Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo. (Funded by Pfizer; ClinicalTrials.gov number, NCT00787202.).